Vasopressin and heart failure
Grant number: 566947 | Funding period: 2009 - 2012
Heart failure (HF) is the most common cause of hospital admission in those over 65y, and has significant morbidity and mortality. We need to develop new strategies to treat HF. Plasma vasopressin (AVP) levels are elevated in HF, and may contribute to adverse outcomes. This proposal will assess the utility of blocking the vasopressin V1 and V2 receptors in a rat model of HF. We shall also measure AVP in humans with HF. The results of this work may result in new approaches to treat HF patients.